Wisconsin Patent of the Month – September 2021

The World Health Organization estimates nearly 300 million people have asthma, worldwide and expect this to rise to 300 million by 2025. Despite new medications and advancements in treatments, hospital visits and deaths due to asthma have not slowed down. Most asthmatics do not have it under control. This is largely because tracking how treatments control symptoms and improve quality of life is quite difficult and rely on patient’s personal reports of symptom frequency, inhaler usage, activity level and more. Reciprocal Labs Corp. have developed a real time adaptive for accurate monitoring of these patients.

They designed and developed an adherence analytics system. It uses a unified platform to monitor medication use (inhaler), analyze this data, and provide relevant notifications based on this. The inhaler is equipped with a sensor to report when it’s used by a patient. It tracks the amount of dose distributed as well as the geographical location, time, and date of use. All of this data is transferred to the analytics system for processing. It takes into consideration the present event as well as past events to form patterns and understand frequency of symptoms. Some patients have two inhalers – one with emergency medication and one with regulating medication. The latter is usually a planned dose, used every morning to help manage asthma. The sensor can then also track if the patient is regularly taking these planned doses or if they are regularly missing them. This provides the most accurate data, helping a physician better understand how their patient is managing their condition without relying on the biased patient report. Their system makes it easier to stick to the treatment plan and helps detect what may be causing flare-ups, hopefully leading to more symptom-free days.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts